Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a studyVolkan Granit, Matthew T. Duvernay, Tuan Vu et al.|The Lancet Neurology|2023Cited by 255